Go Pro
NASDAQ:REVB

Revelation Biosciences Q2 2026 Earnings Report

Revelation Biosciences logo
$1.15 +0.02 (+1.77%)
Closing price 04:00 PM Eastern
Extended Trading
$1.13 -0.02 (-1.74%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revelation Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.83
Beat/Miss
N/A
One Year Ago EPS
N/A

Revelation Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Revelation Biosciences Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Revelation Biosciences Earnings Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
REVB Poised for Big Year
See More Revelation Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email.

About Revelation Biosciences

Revelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

View Revelation Biosciences Profile